Literature DB >> 30838504

Prevalence and morphology of myocardial crypts in normal and hypertrophied myocardium by computed tomography.

Ziad Arow1,2, Mithal Nassar1,2, Daniel Monakier1,2, Abid Assali1,2, Hana Vaknin-Assa1,2, Ran Kornowski1,2, Ashraf Hamdan3,4.   

Abstract

Myocardial crypts can be recognized in patients with hypertrophic cardiomyopathy (HCM) using magnetic resonance imaging, but similar studies using computed tomography (CT) are sparse. The aim of the present study was to evaluate the prevalence and morphology of myocardial crypts in patients with HCM, arterial hypertension, and aortic valve stenosis using contrast-enhanced CT. We also investigated the added value of a finding of myocardial crypts on CT scan to the diagnosis of HCM. The study cohort included 73 patients with HCM, 100 patients with arterial hypertension, 120 patients with aortic valve stenosis, and 100 subjects without cardiovascular disease (normal control group). All underwent evaluation for the presence and dimensions of myocardial crypts using 256-slice CT. Crypts were identified in 18 patients (24.7%) with HCM, 7 patients (7%) with hypertension, 8 patients (6.7%) with aortic valve stenosis, and 4 (4%) normal subjects (P < 0.001). Values of crypt length, width, area, and penetration into myocardium were highest in the HCM group. Crypt area differentiated patients with HCM from patients with arterial hypertension and aortic valve stenosis, and from normal control subjects. Crypt area was an accurate predictor of HCM, with an area under the receiver-operator characteristic curve of 0.88 (95% CI 0.80-0.96). Myocardial crypts identified by CT are more prevalent and larger in area in HCM than in arterial hypertension and aortic valve stenosis. Crypt area could potentially help to improve the diagnosis of HCM by CT beyond the assessment of left ventricular thickness or mass.

Entities:  

Keywords:  Aortic valve stenosis; Computed tomography; Hypertrophic cardiomyopathy; Left ventricular hypertrophy; Myocardial crypts

Mesh:

Year:  2019        PMID: 30838504     DOI: 10.1007/s10554-019-01543-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  19 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy.

Authors:  T Kuribayashi; W C Roberts
Journal:  Am J Cardiol       Date:  1992-11-15       Impact factor: 2.778

3.  Asymmetrical hypertrophy of the heart in young adults.

Authors:  D TEARE
Journal:  Br Heart J       Date:  1958-01

4.  Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers.

Authors:  Wessel P Brouwer; Tjeerd Germans; Maaike C Head; Jolanda van der Velden; Martijn W Heymans; Imke Christiaans; Arjan C Houweling; Arthur A Wilde; Albert C van Rossum
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-01-24       Impact factor: 6.875

5.  Congenital left ventricular wall abnormalities in adults detected by gated cardiac multidetector computed tomography: clefts, aneurysms, diverticula and terminology problems.

Authors:  Cengiz Erol; Mustafa Koplay; Ayhan Olcay; Ali Sami Kivrak; Seda Ozbek; Mehmet Seker; Yahya Paksoy
Journal:  Eur J Radiol       Date:  2012-04-23       Impact factor: 3.528

6.  Ventricular diverticula on cardiac CT: more common than previously thought.

Authors:  Monvadi B Srichai; Elizabeth M Hecht; Danny C Kim; Jill E Jacobs
Journal:  AJR Am J Roentgenol       Date:  2007-07       Impact factor: 3.959

7.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  Eur Heart J       Date:  2007-10-24       Impact factor: 29.983

8.  Clefts can be seen in the basal inferior wall of the left ventricle and the interventricular septum in healthy volunteers as well as patients by cardiovascular magnetic resonance.

Authors:  Bengt Johansson; Alicia M Maceira; Sonya V Babu-Narayan; James C Moon; Dudley J Pennell; Philip J Kilner
Journal:  J Am Coll Cardiol       Date:  2007-09-10       Impact factor: 24.094

9.  Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.

Authors:  Tjeerd Germans; Arthur A M Wilde; Pieter A Dijkmans; Wenxia Chai; Otto Kamp; Yigal M Pinto; Albert C van Rossum
Journal:  J Am Coll Cardiol       Date:  2006-11-28       Impact factor: 24.094

10.  Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; David Lin; Evan Appelbaum; Raymond H Chan; C Michael Gibson; John R Lesser; Jana Lindberg; Tammy S Haas; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Cardiovasc Imaging       Date:  2012-05-04       Impact factor: 7.792

View more
  1 in total

1.  Cardiovascular imaging 2019 in the International Journal of Cardiovascular Imaging.

Authors:  Johan H C Reiber; Gabriel T R Pereira; Luis A P Dallan; Hiram G Bezerra; Johan De Sutter; Arthur E Stillman; Nico R L Van de Veire; Joachim Lotz
Journal:  Int J Cardiovasc Imaging       Date:  2020-05       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.